Skip to main content
Moleculin Bio seeks FDA's fast-track status for AML drug Annamycin
3/14/2019

Moleculin Biotech has filed a request with the FDA seeking accelerated review status for its drug candidate Annamycin as a treatment for relapsed/refractory acute myeloid leukemia.

Full Story: